Nuvectis Pharma Net Income
| NVCT Stock | USD 8.77 0.03 0.34% |
As of the 13th of February 2026, Nuvectis Pharma secures the Downside Deviation of 2.85, mean deviation of 2.61, and Risk Adjusted Performance of 0.1466. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Nuvectis Pharma, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Nuvectis Pharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nuvectis Pharma's valuation are summarized below:There are currently ninety-one fundamental ratios for Nuvectis Pharma that can be evaluated and compared over time across peers in the industry. All traders should check Nuvectis Pharma's last-minute fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 172.9 M in 2026. Enterprise Value is likely to gain to about 139.7 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -17.2 M | -16.3 M | |
| Net Loss | -26.4 M | -27.8 M | |
| Net Loss | -17.1 M | -18 M | |
| Net Loss | (1.32) | (1.39) |
Nuvectis | Net Income | Build AI portfolio with Nuvectis Stock |
The evolution of Net Income for Nuvectis Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Nuvectis Pharma compares to historical norms and industry peers.
Latest Nuvectis Pharma's Net Income Growth Pattern
Below is the plot of the Net Income of Nuvectis Pharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Nuvectis Pharma financial statement analysis. It represents the amount of money remaining after all of Nuvectis Pharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Nuvectis Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvectis Pharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (26.44 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Nuvectis Net Income Regression Statistics
| Arithmetic Mean | (7,608,321) | |
| Coefficient Of Variation | (146.11) | |
| Mean Deviation | 9,833,121 | |
| Median | (10,000) | |
| Standard Deviation | 11,116,535 | |
| Sample Variance | 123.6T | |
| Range | 28.9M | |
| R-Value | (0.85) | |
| Mean Square Error | 37.4T | |
| R-Squared | 0.72 | |
| Significance | 0.000018 | |
| Slope | (1,863,462) | |
| Total Sum of Squares | 1977.2T |
Nuvectis Net Income History
Other Fundumenentals of Nuvectis Pharma
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Nuvectis Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Nuvectis Pharma is extremely important. It helps to project a fair market value of Nuvectis Stock properly, considering its historical fundamentals such as Net Income. Since Nuvectis Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Nuvectis Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Nuvectis Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Nuvectis introduce new products? Factors like these will boost the valuation of Nuvectis Pharma. Anticipated expansion of Nuvectis directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about Nuvectis Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Understanding Nuvectis Pharma requires distinguishing between market price and book value, where the latter reflects Nuvectis's accounting equity. The concept of intrinsic value - what Nuvectis Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Nuvectis Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Nuvectis Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Nuvectis Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Nuvectis Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Nuvectis Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Nuvectis Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Nuvectis Pharma.
| 11/15/2025 |
| 02/13/2026 |
If you would invest 0.00 in Nuvectis Pharma on November 15, 2025 and sell it all today you would earn a total of 0.00 from holding Nuvectis Pharma or generate 0.0% return on investment in Nuvectis Pharma over 90 days. Nuvectis Pharma is related to or competes with Innate Pharma, Compugen, Milestone Pharmaceuticals, Rani Therapeutics, Cardiff Oncology, Armata Pharmaceuticals, and Molecular Partners. Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment ... More
Nuvectis Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Nuvectis Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Nuvectis Pharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 2.85 | |||
| Information Ratio | 0.1482 | |||
| Maximum Drawdown | 17.53 | |||
| Value At Risk | (4.41) | |||
| Potential Upside | 6.17 |
Nuvectis Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nuvectis Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Nuvectis Pharma's standard deviation. In reality, there are many statistical measures that can use Nuvectis Pharma historical prices to predict the future Nuvectis Pharma's volatility.| Risk Adjusted Performance | 0.1466 | |||
| Jensen Alpha | 0.5097 | |||
| Total Risk Alpha | 0.288 | |||
| Sortino Ratio | 0.1851 | |||
| Treynor Ratio | 0.4804 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Nuvectis Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Nuvectis Pharma February 13, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1466 | |||
| Market Risk Adjusted Performance | 0.4904 | |||
| Mean Deviation | 2.61 | |||
| Semi Deviation | 2.4 | |||
| Downside Deviation | 2.85 | |||
| Coefficient Of Variation | 584.93 | |||
| Standard Deviation | 3.55 | |||
| Variance | 12.63 | |||
| Information Ratio | 0.1482 | |||
| Jensen Alpha | 0.5097 | |||
| Total Risk Alpha | 0.288 | |||
| Sortino Ratio | 0.1851 | |||
| Treynor Ratio | 0.4804 | |||
| Maximum Drawdown | 17.53 | |||
| Value At Risk | (4.41) | |||
| Potential Upside | 6.17 | |||
| Downside Variance | 8.1 | |||
| Semi Variance | 5.75 | |||
| Expected Short fall | (3.02) | |||
| Skewness | 0.8022 | |||
| Kurtosis | 1.5 |
Nuvectis Pharma Backtested Returns
Nuvectis Pharma appears to be somewhat reliable, given 3 months investment horizon. Nuvectis Pharma has Sharpe Ratio of 0.18, which conveys that the firm had a 0.18 % return per unit of risk over the last 3 months. By analyzing Nuvectis Pharma's technical indicators, you can evaluate if the expected return of 0.68% is justified by implied risk. Please exercise Nuvectis Pharma's Downside Deviation of 2.85, mean deviation of 2.61, and Risk Adjusted Performance of 0.1466 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Nuvectis Pharma holds a performance score of 14. The company secures a Beta (Market Risk) of 1.24, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Nuvectis Pharma will likely underperform. Please check Nuvectis Pharma's sortino ratio, downside variance, as well as the relationship between the Downside Variance and rate of daily change , to make a quick decision on whether Nuvectis Pharma's current price movements will revert.
Auto-correlation | 0.32 |
Below average predictability
Nuvectis Pharma has below average predictability. Overlapping area represents the amount of predictability between Nuvectis Pharma time series from 15th of November 2025 to 30th of December 2025 and 30th of December 2025 to 13th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Nuvectis Pharma price movement. The serial correlation of 0.32 indicates that nearly 32.0% of current Nuvectis Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.32 | |
| Spearman Rank Test | 0.25 | |
| Residual Average | 0.0 | |
| Price Variance | 0.12 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Nuvectis Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Nuvectis Pharma reported net income of (26.44 Million). This is 107.75% lower than that of the Biotechnology sector and 137.75% lower than that of the Health Care industry. The net income for all United States stocks is 104.63% higher than that of the company.
Nuvectis Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nuvectis Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nuvectis Pharma could also be used in its relative valuation, which is a method of valuing Nuvectis Pharma by comparing valuation metrics of similar companies.Nuvectis Pharma is currently under evaluation in net income category among its peers.
Nuvectis Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Nuvectis Pharma from analyzing Nuvectis Pharma's financial statements. These drivers represent accounts that assess Nuvectis Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Nuvectis Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Enterprise Value | 35.6M | 74.9M | 110.6M | 74.0M | 133.1M | 139.7M |
Nuvectis Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Nuvectis Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Nuvectis Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Nuvectis Pharma Institutional Holders
Institutional Holdings refers to the ownership stake in Nuvectis Pharma that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Nuvectis Pharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Nuvectis Pharma's value.| Shares | Renaissance Technologies Corp | 2025-06-30 | 43 K | Gsa Capital Partners Llp | 2025-06-30 | 39.2 K | Charles Schwab Investment Management Inc | 2025-06-30 | 38 K | Royal Bank Of Canada | 2025-06-30 | 31.2 K | Millennium Management Llc | 2025-06-30 | 31.2 K | Bank Of New York Mellon Corp | 2025-06-30 | 27.2 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 24.7 K | Barclays Plc | 2025-06-30 | 23.2 K | Austin Wealth Management Llc | 2025-06-30 | 20.1 K | Vanguard Group Inc | 2025-06-30 | 666.8 K | Blackrock Inc | 2025-06-30 | 643 K |
Nuvectis Fundamentals
| Return On Equity | -1.88 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 189.46 M | ||||
| Shares Outstanding | 25.61 M | ||||
| Shares Owned By Insiders | 42.09 % | ||||
| Shares Owned By Institutions | 16.98 % | ||||
| Number Of Shares Shorted | 1.59 M | ||||
| Price To Book | 9.37 X | ||||
| EBITDA | (19 M) | ||||
| Net Income | (26.44 M) | ||||
| Cash And Equivalents | 13.57 M | ||||
| Cash Per Share | 0.93 X | ||||
| Total Debt | 13.3 M | ||||
| Current Ratio | 5.20 X | ||||
| Book Value Per Share | 0.72 X | ||||
| Cash Flow From Operations | (16.01 M) | ||||
| Short Ratio | 21.18 X | ||||
| Earnings Per Share | (1.37) X | ||||
| Target Price | 16.8 | ||||
| Number Of Employees | 13 | ||||
| Beta | -0.3 | ||||
| Market Capitalization | 224.9 M | ||||
| Total Asset | 31.71 M | ||||
| Retained Earnings | (99.69 M) | ||||
| Working Capital | 9.71 M | ||||
| Net Asset | 31.71 M |
About Nuvectis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nuvectis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nuvectis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nuvectis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.